Abstract
Opioid receptors are seven-transmembrane domain receptors that couple to intracellular signaling molecules by activating heterotrimeric G proteins. However, the receptor and G protein do not function in isolation but their activities are modulated by several accessory and scaffolding proteins. Examples include arrestins, kinases, and regulators of G protein signaling proteins. Accessory proteins contribute to the observed potency and efficacy of agonists, but also to the direction of signaling and the phenomenon of biased agonism. This review will present current knowledge of such proteins and how they may provide targets for future drug design.
Keywords: Opioid receptors, regulator of G protein signaling proteins, arrestins, G protein-coupled receptor kinases, protein kinase C, biased agonism, drug discovery.
Current Pharmaceutical Design
Title:Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Volume: 19 Issue: 42
Author(s): Jennifer T. Lamberts and John R. Traynor
Affiliation:
Keywords: Opioid receptors, regulator of G protein signaling proteins, arrestins, G protein-coupled receptor kinases, protein kinase C, biased agonism, drug discovery.
Abstract: Opioid receptors are seven-transmembrane domain receptors that couple to intracellular signaling molecules by activating heterotrimeric G proteins. However, the receptor and G protein do not function in isolation but their activities are modulated by several accessory and scaffolding proteins. Examples include arrestins, kinases, and regulators of G protein signaling proteins. Accessory proteins contribute to the observed potency and efficacy of agonists, but also to the direction of signaling and the phenomenon of biased agonism. This review will present current knowledge of such proteins and how they may provide targets for future drug design.
Export Options
About this article
Cite this article as:
Lamberts T. Jennifer and Traynor R. John, Opioid Receptor Interacting Proteins and the Control of Opioid Signaling, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/138161281942140105160625
DOI https://dx.doi.org/10.2174/138161281942140105160625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Vector Delivery Methods and Targeting Strategies for Gene Therapy of Brain Tumors
Current Gene Therapy Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
Current Pharmaceutical Design Alpha-Particle Microdosimetry
Current Radiopharmaceuticals Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design A Review on Anti-urease Potential of Coumarins
Current Drug Targets Novel Phospholipid-Based Labrasol Nanomicelles Loaded Flavonoids for Oral Delivery with Enhanced Penetration and Anti-Brain Tumor Efficiency
Current Drug Delivery Neurosteroids and Hepatic Encephalopathy: An Update on Possible Pathophysiologic Mechanisms
Current Molecular Pharmacology Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets EDITORIAL (Hot Topic: Cancer Chemoresistance and DNA Repair)
Current Medicinal Chemistry Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets